FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma

MRD-guided therapy debate

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

Cabozantinib in combination with atezolizumab in patients with mCRPC

OncoAlert and ecancer - ESMO 2021 Day 2

Long-term outcomes and complications in cancer patients who have recovered from COVID-19

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer